¿ Agilent Technologies Inc. and Incyte Genomics Inc., both of Palo Alto, Calif., expanded their licensing agreement to further Agilent¿s development and commercialization of gene expression microarrays using Incyte¿s gene patent portfolio and genomic databases. Incyte will receive additional license fees as well as royalties on sales of Agilent microarrays.
¿ BioDiscovery Inc., of Marina Del Rey, Calif., reported that Oregon Health & Science University¿s Gene Microarray Resource Facility in Portland is using the company¿s CloneTracker, ImaGene and GeneSight software for the analysis of gene expression data generated by the facility. BioDiscovery develops software for microarray research.
¿ Biogen Inc., of Cambridge, Mass., and Elan Corp. plc, of Dublin, Ireland, released more-detailed, promising results from their Phase II study of Antegren in multiple sclerosis. Antegren, an alpha-4 integrin inhibitor, was designed to prevent migration of inflammatory cells from blood vessels into tissues. Elan conducted a Phase II, double-blind, placebo-controlled trial of 213 MS patients at 26 sites in the U.S., Canada and the UK. The companies, which also have presented positive Phase II data in Crohn¿s disease, said they plan to move into Phase III trials soon. (See BioWorld Today, Jan. 24, 2001, and May 24, 2001.)
¿ Cel-Sci Corp., of Vienna, Va., said its cooperative research and development agreement with the Naval Medical Research Center of the U.S. Navy to develop a malaria vaccine using the company¿s LEAPS (Ligand Epitope Antigen Presentation System) technology has been extended for a third time. LEAPS is a T-cell modulation platform technology that allows Cel-Sci to design and synthesize proprietary immunogens.
¿ Chromos Molecular Systems Inc., of Burnaby, British Columbia, reported publishing a paper titled ¿Efficient in-vitro transfer of a 60-Mb mammalian artificial chromosome into murine and hamster cells using cationic lipids and dendrimers¿ in the August edition of Chromosome Research. The company said the research demonstrates that artificial chromosomes containing selected genes successfully can be delivered to target cells in vitro using a variety of agents to mediate the transfer.
¿ Exten Industries Inc., of San Diego, said it finalized its acquisition of all outstanding shares of MultiCell Associates Inc., of Warwick, R.I., and will operate MCA as a wholly owned subsidiary. MCA owns the rights to certain patented technology for engineering human and other mammalian liver cells. These non-tumorigenic cells have applications for drug discovery and toxicological testing and could perform metabolic functions in liver-assist devices. Further, the cells have shown the ability to generate very complex proteins that have a variety of therapeutic and research applications. Terms were not disclosed.
¿ GeneData AG, of Basel, Switzerland, and Bayer AG, of Leverkusen, Germany, said they successfully identified and prioritized more than 150 targets for antibacterial drug discovery. The collaboration is focused on the identification of new classes of antibiotics to treat infectious diseases, particularly those caused by pathogens resistant to current therapies. The companies extended their collaboration in microbial genomics by another three years in order to evaluate the identified drug candidates.
¿ Hollis-Eden Pharmaceuticals Inc., of San Diego, entered a private equity line of credit with an institutional investor for the purchase of up to $10 million of common stock during the next 18 months. The company said the funds can be drawn down in formula-based increments, at its discretion, at a small discount to market.
¿ Immunex Corp., of Seattle, and Wyeth-Ayerst Laboratories, a division of Madison, N.J.-based American Home Products Corp., said that the FDA granted priority review status for Immunex¿s supplemental biologics license application to use Enbrel in the treatment of psoriatic arthritis. Priority review status indicates that the FDA will act on the Enbrel supplemental BLA within six months of the submission date. Enbrel is the first product ever reviewed by the FDA to treat the signs and symptoms of psoriatic arthritis, the company said. The sBLA was filed in July. (See BioWorld Today, July 18, 2001.)
¿ MorphoSys AG, of Martinsried, Germany, formed an agreement with Oridis Biomed Forschungs-und Entwicklungs GmbH, of Graz, Austria, to provide MorphoSys with access to one of the world¿s largest tissue banks. MorphoSys will apply its HuCal technology to make antibodies to candidate targets, which Oridis Biomed will use to perform high-throughput protein expression analysis on a range of human tissue. Oridis Biomed will receive a license to the HuCal technology and will have access to certain antibodies from MorphoSys. MorphoSys receives first right of negotiation on all antibody products resulting from the collaboration. Terms were not disclosed.
¿ Phytomedics Inc., of Dayton, N.J., said it signed an agreement with Bristol-Myers Squibb Co., of New York, to test the production of therapeutic proteins using Phytomedics¿ plant-based recombinant proteins secretion technology. Phytomedics has been funding the development of the Repost technology at Rutgers University. Repost uses genetically transformed live green plants to synthesize and continuously secrete large quantities of biopharmaceutical proteins from roots into a hydroponic solution composed of water and low amounts of fertilizer.
¿ Thales Industrial Services, of Arcueil, France, and Proteus International, of Nimes, France, said they signed a collaborative agreement to develop a novel system using genetic technologies to detect and monitor biological terrorism. This collaborative agreement has been entered into within the framework of a public tender from the French Direction General des Armees of the Department of Defense of the French Republic.
¿ Tripep AB, of Huddinge, Sweden, reported negative results in the Phase II study of its GPG treatment for HIV. Out of the 27 patients, only three met the study¿s positive response criteria. As a result, the company canceled its planned clinical program for GPG. Tripep said it plans to analyze the results to determine if there is a basis for continued research in certain groups of HIV patients.